



Department of  
**Health, Social Services  
and Public Safety**

[www.dhsspsni.gov.uk](http://www.dhsspsni.gov.uk)

From The Chief Pharmaceutical Officer  
Dr Norman Morrow  
Castle Buildings  
Upper Newtownards Road  
Belfast BT4 3SJ

Telephone: 028 90 523219  
Facsimile: 028 90 522335

E-Mail: [norman.morrow@dhsspsni.gov.uk](mailto:norman.morrow@dhsspsni.gov.uk)

Our Ref: PHC/23/2011

Date: 26 August 2011

**For Action:** Assistant Director Pharmacy and Medicines Management,  
HSC Board & BSO  
Heads of Pharmacy and Medicines Management of  
HSC Trusts  
Regulation Quality Improvement Authority

## **DRUG ALERT MEDICINES RECALL**

Dear Healthcare Professional

### **RECKITT BENCKISER (UK) LTD**

**Nurofen Plus Tablets containing rogue Seroquel XL 50mg tablets and Neurontin 100mg capsules**

### ***PL 00327/0082 and PL 00063/0376***

Following the recent issue of a Drug Alert on 25<sup>th</sup> August (PHC/22/2011) Reckitt Benckiser (UK) Ltd have received further reports of rogue blister strips in cartons of two additional batches of Nurofen Plus tablets. One of the new batches contained Seroquel XL 50 mg tablets and one contained the Pfizer product Neurontin 100mg capsules.

Following discussions with DMRC, Reckitt Benckiser (UK) Ltd have decided to recall all remaining unexpired stock of Nurofen Plus tablets in any pack size.

Recipients are requested to contact patients wherever possible and ask them to return any Nurofen Plus tablets to the pharmacy where they were purchased or dispensed.

Wholesalers are requested to return any remaining stock to their original supplier for credit.

For medical information enquiries related to Seroquel XL Tablets please contact AstraZeneca Ltd medical information department on 0800 783 0033.


For medical information enquiries related to Neurontin 100mg capsules please contact Pfizer medical information department on 01304 616161.

For medical information enquiries related to Nurofen Plus Tablets please contact Reckitt Benckiser (UK) Ltd medical information department on 0500 455 456.

The HSC Board/RQIA should bring this information to the attention of private hospitals/clinics registered with them and any other relevant care facilities.

The Business Services Organisation is asked to bring this information to the attention of Community Pharmacists and General Medical practitioners directly.

Yours sincerely



**DR NORMAN MORROW**  
Chief Pharmaceutical Officer

For information:

CMO  
CNO  
CDO  
CSSO  
SMO  
Director, Health Estates  
Public Health Branch  
DHSSPS, Library  
Extended nurse prescribers

Regional Medicines and Poisons Information Service  
Regional Director of Supplies  
RPQAS  
Pharmaceutical Society of NI  
Senior Prison Pharmacist  
Prison Service, Dundonald House  
Nursing Officer, Health Estates  
Medical Officer, Castle Buildings  
Regional Procurement Pharmacist  
NICPLD